CollPlant Biotechnologies Ltd. appointed Dr. Ruti Ben Shlomi to its Board of Directors on September 4, 2026, effective immediately following the closing of its acquisition of LightSolver Ltd., announced on September 3, 2026. Dr. Ben Shlomi serves as CEO and Co-Founder of LightSolver, a company pioneering high-performance photonic computing using Laser Processing Units (LPUs). This appointment supports CollPlant's strategy to commercialize the acquired deep-tech assets alongside its existing regenerative medicine business. CollPlant Biotechnologies Ltd. operates in the biotechnology and advanced technology sectors, focusing on recombinant human collagen for medical applications and all-optical computing architectures.

CollPlant Biotechnologies Ltd completed its acquisition of LightSolver Ltd on September 3, 2026, pursuant to a Share Purchase Agreement dated August 29, 2026. The transaction utilized an equity-centric structure, involving the issuance of upfront ordinary shares and pre-funded warrants, along with a $5 million cash investment in LightSolver. Additional milestone-based warrants are exercisable upon LightSolver achieving specified technological and commercial objectives. This acquisition marks CollPlant's entry into the high-performance computing and photonics sectors through LightSolver’s Laser Processing Unit technology. CollPlant Biotechnologies Ltd operates in the biotechnology industry, focusing on regenerative medicine and plant-based recombinant human collagen production.

CollPlant Biotechnologies Ltd. entered into a Share Purchase Agreement on August 29, 2026, to acquire LightSolver Ltd., a developer of photonic computing technology. The acquisition is expected to close in late August 2026. Consideration includes 3,734,476 ordinary shares (19.7% of pre-transaction outstanding shares), pre-funded warrants for 6,134,363 shares, and milestone-based warrants for up to 224,078,345 shares. Roli over options for 2,261,966 shares were also issued. Dr. Ruti Ben Shlomi joined CollPlant's board upon closing. This transaction marks CollPlant's entry into the supercomputing and photonics markets while maintaining its regenerative medicine business.

CollPlant Biotechnologies Ltd. announced an extraordinary general meeting of shareholders for August 18, 2026, to vote on a reverse stock split and the elimination of par value. The company received a non-compliance notice from Nasdaq on March 23, 2026, due to its closing bid price falling below $1.00 for 30 consecutive business days. To regain compliance by the September 21, 2026 deadline, the board approved a reverse split framework ranging from 1-for-8 to 1-for-12, with the exact ratio and effective date to be determined by the board following shareholder approval. The filing also proposes amending the company's articles of association to eliminate the par value of its share capital. CollPlant Biotechnologies Ltd. operates in the biotechnology industry, specializing in the production of spider silk proteins for various applications.